Europa Trial
Home
Sitemap
General Public Heathcare Professionals Virtual Press Office

New Indication in CAD

EUROPA calendar
ACC 2006 - Posters
ESC 2005 - Symposium
ESC 2005 - Oral sessions
ESC 2005 - Posters
AHA 2004 - Oral Session
ESC 2004 - Hotline
ESC 2004 - Symposium
ACC 2004
ESC 2003


EUROPA study
EUROPA Results
ESC 2003 Hotline - video
Rationale for EUROPA
Rationale for Perindopril
Design & Organisation
EUROPA investigators
EUROPA collaborating centres
EUROPA Recruitment


EUROPA Slide Set
Rationale and Design
Results
Clinical Implications


EUROPA publications


PERSUADE
PERSUADE Publications
PERSUADE Results
PERSUADE Fact Sheet


PERTINENT
PERTINENT Results
PERTINENT Fact Sheet


Background : Coronary Artery Disease
Home : Healthcare professionals : ESC 2005 - Oral Sessions
ESC 2005 - Oral Sessions

Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk

Authors:
J W Deckers, DM Goedhart, ME Bertrand1, R Ferrari2, K Fox3, WJ Remme4, ML Simoons, Erasmus MC - Rotterdam - Netherlands, 1University of Lille - Lille - France, 2University of Ferrara - Ferrara - Italy, 3Royal Brompton Hospital - London - United Kingdom, 4Sticares Cardiovascul Res Foundation - Rotterdam - Netherlands,

Topic(s):
ACE inhibitors and AT2 blockers
Epidemiology / prevention, other
Prognosis, risk assessment
Adjunctive medical therapy

Patients with stable coronary artery disease (CAD) are at increased risk for recurrent cardiac events. However, estimation of individual risk is difficult, and assessment of absolute treatment benefit thus complex.

For these reasons, we developed a cardiovascular risk model, and investigated whether benefit associated with long-term administration of the ACE inhibitor perindopril was modified by risk level.

Study population: 12.218 patients (age range 26 to 86 years) with stable CAD (no heart failure or hypertension) treated with 8 mg perindopril or placebo.

Baseline patient characteristics were assessed for association with 1.090 cardiovascular deaths or non-fatal MI accruing over 50.000 years of follow-up.

Major risk factors: age over 65 years, male gender (RR 1,2), previous MI (RR 1,4), previous stroke or PVD (RR 2,0), diabetes (1,8), smoking (1,4), angina (RR 1,7), elevated serum cholesterol and systolic BP. Risk was reduced in patients with previous revascularization and on lipid lowering therapy (both RR 0,7).

Patients were categorized in tertiles (approximately 4.000 patients each) of modeled risk. Results are given in the table.

Conclusions: Treatment benefit by perindopril was consistent (risk reduction 20%) among high, intermediate and low risk patients. Reduction of risk was thus not modified by absolute level of risk.

Risk tertile

Perindopril

Placebo

Risk Reduction

1

4,3%

5,0%

15%

2

6,3%

9,4%

34%

3

13,5%

15,2%

11%


Back



This website is intended for an international audience. Drug related information may refer to unlicensed products or uses which may not be approved in your own country and you should therefore consult your local prescribing information.
This site is published and updated by the EUROPA study investigators. Site last updated March 21st 2006
Terms of use - ©2005 EUROPA All rights reserved